Related Experiment Video
Updated: Dec 13, 2025

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Published on: October 29, 2019
Correction to: Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders
Flavien Bizot1, Adeline Vulin1,2, Aurélie Goyenvalle3,4
1Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000, Versailles, France.
Abstract:
The second author, which currently reads as: Adeline Vulin-Chaffiol.
More Related Videos
07:02Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Satellite Stem Cells and Muscular Dystrophy
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses
Neuromuscular Junction And Blockade
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...